MRI Assessment of Leukemia Response to Therapy

CompletedOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Acute Myelogenous Leukemia
Interventions
DEVICE

3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system

Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

OHSU Knight Cancer Institute

OTHER

NCT01537159 - MRI Assessment of Leukemia Response to Therapy | Biotech Hunter | Biotech Hunter